title: [Risk factors for side effects of long-term administration of 5-fluorouracil derivatives in patients with hepatocellular carcinoma associated with liver cirrhosis--relationship with serum concentration of anti-tumor agents and side effect].
authors.forename: K
authors.initials: K
authors.lastname: Ikeda
authors.forename: H
authors.initials: H
authors.lastname: Kumada
authors.forename: Y
authors.initials: Y
authors.lastname: Arase
authors.forename: K
authors.initials: K
authors.lastname: Chayama
authors.forename: T
authors.initials: T
authors.lastname: Gunji
authors.forename: A
authors.initials: A
authors.lastname: Yoshiba
authors.forename: M
authors.initials: M
authors.lastname: Irimoto
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D001201:Ascites / Q000139:chemically induced; D001927:Brain Diseases / Q000139:chemically induced; D006528:Carcinoma, Hepatocellular / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications*; D008113:Liver Neoplasms / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D005641:Tegafur / Q000009:adverse effects* / Q000097:blood; D013997:Time Factors; D014498:Uracil / Q000009:adverse effects
chemical_list: D005641:Tegafur; D014498:Uracil